Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLB 001 randomized double-blind placebo-controlled multiple ascending dose LPS challenge study in healthy volunteers
NL-OMON51741Active, not recruiting
- Sponsor
- ORPH Pharma IP Company
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial comparing POLB 001 with Placebo (2 arms). Primary endpoints: Skin perfusion response, Skin erythema response and 13 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
POLB 001
Beyond the preview
Go deeper on NL-OMON51741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51741.